Hailey Caprara discusses the usefulness of NIRS imaging in the management of patients with or at risk of pressure injuries. She discussed the advantage of a proactive tissue imaging approach for early detection of possible injury.

Dr Matthew Regulski discusses his recent poster at the SWAC Spring 2026 conference. The poster is entitled Peptide Biomimetic Matrix Revitalizes Chronic Wounds via Tissue Regrowth and Revascularization: Monitoring Progress with Multispectral NIRS Imaging and demonstrates the usefulness of NIRS imaging in tracking wound progress in real time.

Learn from the MIMOSA Diagnostics Co-founders the challenges they faced starting and growing the company. Also hear about their vision for the future of both the product and the company.

Learn from the co-founders of MIMOSA Diagnostics how the company evolved and grew from the original genesis of the idea.

Learn how NIRS imaging drove health equity for patients regarding possible pressure injuries. MIMOSA Pro was agnostic to skin tone helping the Hamilton Health Sciences organisation address their need for equitable healthcare across their patient population.

Hamilton Health Sciences trialled MIMOSA Pro as a potential tool for the early detection of pressure injuries across all skin tones. Learn from the three speakers how their 3500 assessment till went.

Dr Karen Cross discussed the terms precision medicine, predictive data and personalized treatment within medicine. Hear how this can be the future of wound management,

Based on her recent SAWC Fall poster Christy Handley discusses the economics of using skin substitutes within her practice. She presents data that supports the usefulness of NIRS imaging in this evaluation.

Christy Handley discusses her recent poster at the SAWC Fall meeting. Hear how NIRS imaging helps with each stage of their 7-step wound process.

Learn about MIMOSA Diagnostics customer driven wound measurement feature enhancements. Understand how important consistent measurement and tracking is within your clinical practice.